Experts discuss the critical advancements in biomarker-driven frontline treatment for high-risk chronic lymphocytic leukemia (CLL), emphasizing the SEQUOIA trial’s evidence supporting targeted Bruton tyrosine kinase inhibitor monotherapy and combination therapies with venetoclax as effective, personalized, and well-tolerated options that improve progression-free survival and patient quality of life.
EP. 2: Interpretation and Clinical Implications of SEQUOIA Arm C Results in CLL/SLL
October 6th 2025Experts discuss how the SEQUOIA trial reinforces Bruton tyrosine kinase (BTK) inhibitor monotherapy as an effective frontline treatment for patients with chronic lymphocytic leukemia (CLL) with deletion 17p, showing progression-free survival (PFS) rates comparable to those without high-risk mutations, and highlighting that second-generation BTK inhibitors can overcome historically poor prognoses without added benefit from anti-CD20 antibodies.
EP. 3: Zanubrutinib + Venetoclax for Treatment-Naive CLL/SLL (SEQUOIA Arm D)
October 13th 2025Experts discuss the promising results of a SEQUOIA trial substudy evaluating Bruton tyrosine kinase (BTK) inhibitor plus venetoclax combination therapy in patients with chronic lymphocytic leukemia (CLL)—including those with TP53 mutations or deletion 17p—highlighting high progression-free survival (PFS), deep minimal residual disease (MRD)-driven remissions, and strong safety outcomes that support this doublet as a flexible, effective frontline option for high-risk disease.
EP. 4: Interpretation and Clinical Implications of SEQUOIA Arm D Results in CLL/SLL
October 20th 2025Experts discuss the growing role of time-limited Bruton tyrosine kinase (BTK) inhibitor plus venetoclax therapy for high-risk chronic lymphocytic leukemia (CLL)—particularly in patients with deletion 17p—emphasizing the SEQUOIA R&D data that support flexible, minimal residual disease (MRD)-guided treatment durations and all-oral regimens as effective, convenient, and patient-centered options for achieving deep, durable responses.